GROSSI, Laurino
 Distribuzione geografica
Continente #
NA - Nord America 4.845
EU - Europa 4.360
AS - Asia 2.458
Continente sconosciuto - Info sul continente non disponibili 21
SA - Sud America 6
AF - Africa 3
OC - Oceania 1
Totale 11.694
Nazione #
US - Stati Uniti d'America 4.827
CN - Cina 968
UA - Ucraina 814
IT - Italia 739
IE - Irlanda 710
TR - Turchia 560
SE - Svezia 554
SG - Singapore 524
GB - Regno Unito 476
FR - Francia 397
IN - India 344
DE - Germania 244
FI - Finlandia 154
RU - Federazione Russa 125
AT - Austria 46
VN - Vietnam 36
PL - Polonia 35
EU - Europa 20
BE - Belgio 18
RO - Romania 15
CA - Canada 9
MX - Messico 9
GR - Grecia 6
IL - Israele 6
NL - Olanda 5
TW - Taiwan 5
CZ - Repubblica Ceca 4
ES - Italia 4
HK - Hong Kong 4
AL - Albania 3
CL - Cile 3
IR - Iran 3
KR - Corea 3
NO - Norvegia 3
AR - Argentina 2
CH - Svizzera 2
JP - Giappone 2
LT - Lituania 2
LU - Lussemburgo 2
AE - Emirati Arabi Uniti 1
AP - ???statistics.table.value.countryCode.AP??? 1
AU - Australia 1
BR - Brasile 1
DK - Danimarca 1
EG - Egitto 1
ID - Indonesia 1
KH - Cambogia 1
MA - Marocco 1
MU - Mauritius 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 11.694
Città #
Jacksonville 943
Chandler 779
Dublin 702
Dearborn 468
Singapore 447
Southend 378
Princeton 354
Nanjing 284
Izmir 272
Wilmington 254
Beijing 169
Cambridge 157
Ashburn 120
Woodbridge 119
Ann Arbor 115
Nanchang 93
Santa Clara 92
Boardman 66
Houston 61
Hebei 53
New York 51
Shenyang 48
Altamura 47
Kunming 45
Vienna 45
Tianjin 43
Rome 42
Jiaxing 40
Kraków 35
Los Angeles 35
Chieti 29
Hefei 29
Hangzhou 27
Bologna 25
Norwalk 25
Dong Ket 22
Düsseldorf 20
Jinan 20
Changsha 18
Orange 18
Brussels 17
Bellante 15
Washington 15
Grevenbroich 14
Guangzhou 14
Lanzhou 14
Milan 14
Vinh 14
Pescara 13
Fuzhou 11
Falls Church 10
Cepagatti 9
Changchun 9
Guadalajara 9
Ningbo 8
Seattle 8
Turin 8
Edinburgh 7
Helsinki 7
L'aquila 7
Mumbai 7
Varallo 7
Auburn Hills 5
Munich 5
Ripa Teatina 5
San Vito al Tagliamento 5
Villamagna 5
Ascoli Piceno 4
Hong Kong 4
Isernia 4
Redwood City 4
Senigallia 4
Siena 4
Simi Valley 4
Sulmona 4
Walnut 4
Xian 4
Zhengzhou 4
Amsterdam 3
Avezzano 3
Baotou 3
Brno 3
Castelfranco di Sotto 3
Cedar Knolls 3
Duncan 3
Frankfurt am Main 3
London 3
Marseille 3
Moscow 3
Mountain View 3
Palermo 3
Taizhou 3
Taranto 3
Teramo 3
Verona 3
Villafranca di Verona 3
Aprilia 2
Ardea 2
Armonk 2
Augusta 2
Totale 6.958
Nome #
Il tempo di transito oro-cecale (TTOC) è accelerato dopo somministrazione orale di allergene alimentare nei pazienti con sindrome del colon irritabile (SCI) e prick test positivo 357
EFFICACY OF TREATMENT WITH PYLERA IN COMBINATION WITH RANITIDINE ON FIRST-LINE INFECTION HELICOBACTER PYLORI: EXPERIENCE OF A SINGLE CENTER 142
SYMPTOM PATTERN IN FUNCTIONAL DYSPEPSIA AND GASTROESOPHAGEAL REFLUX DISEASE: ROLE OF H. PYLORI INFECTION 116
Blood cardioplegia: could it protect the ischemic-reperfused human myocardium through antioxidant-type mechanisms? 110
In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy 110
A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study 110
SR140333, a substance P receptor antagonist, influences morphological and motor changes in rat experimental colitis 110
Trasmissione di Helicobacter pylori in un modello murino 108
24-hour pancolonic motility using a portable electronic probe in healthy subjects 104
48-Hour continuous pH measurement in patients with gastro-oesophageal reflux: effect of cisapride. 104
Helicobacter pylori isolates from proximal and distal stomach of patients never treated and already treated show genetic variability and discordant antibiotic resistance. 102
ITALIAN REAL-LIFE STUDY EVALUATING THE LONG-TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: THE ELDERLY COHORT 101
Ottimizzazione di vedolizumab in RCU con perdita di risposta a infliximab 100
Detection of Helicobacter pylori in the gastrointestinal tract of Balb/C euthymic mice infected by human Helicobacter pylori and evidence for transmission 98
Alterazioni non litiasiche del contenuto colecistico 95
USO DI GOLIMUMAB COME SECONDA LINEA BIOLOGICA IN UN PAZIENTE CON RETTOCOLITE ULCEROSA 95
Treatment of Helicobacter pylori (Hp) infection with an association of Omeprazole and Roxytromicine: a study in vivo and in vitro. 94
FUSOBACTERIUM NUCLEATUM (FN) IN PATIENTS AFFECTED BY INFLAMMATORY BOWEL DISEASE 94
Correlation between anal canal size and anal canal pressure: an ultrasonografhip and manometric study 93
Two weeks regimen with amoxillicin, tinidazole and omeprazole eradicates helicobacter pylori and cures active duodenal ulcer 92
Morphological and motor changes during experimental colits in rats are prevented by a specific substance p antagonist 90
ESOPHAGITIS AND ITS CAUSES: WHO IS "GUILTY" WHEN ACID IS FOUND "NOT GUILTY"? 89
Effect of omeprazole, clarithromicin and amoxicillin for a short time on helicobacter pylori eradication 88
THE INFLUENCE OF ACID REFLUX ON THE HEART RATE VARIABILITY (HRV) IN PATIENTS WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE (GERD). 88
Beneficial effects of SR140333, a novel substance P antagonist, in a rat model of experimental colitis 86
Transmission of Helicobacter pylori in an animal model. 86
Diameters and pressures of the anal canal simultaneously measured with endosonography and manometry 85
REAL-LIFE STUDY (GORE-UC) EVALUATING THE EFFECTIVENESS OF GOLIMUMAB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM ITALIAN GROUP FOR THE STUDY OF INFLAMMATORY BOWEL DISEASE (IG-IBD). 85
Anal canal diameters and pessure measured simultaneously by real time ultrasonography and manometry in human subjects 83
Anti-Helicobacter pylori specific antibody immunohistochemistry improves the diagnostic accuracy of Helicobacter pylori in biopsy specimen from patients treated with triple therapy.Am. J. Gastroenterol 83
MIGRATING MOTOR COMPLEX RECORDED SPONTANEOUSLY AND INDUCED BY MOTILIN AND ERYTHROMYCIN IN AN EX VIVO RABBIT INTESTINAL PREPARATION 83
Distribuzione transmurale dei sistemi antiossidanti e della perossidazione lipidica nel ventricolo sinistro di coniglio 83
THERAPY-RELATED ADVERSE EVENTS IN CROHN’S DISEASE (CD) – A COMPARISON BETWEEN THIOPURINES, INFLIXIMAB AND COMBINED THERAPY 82
Detection of Helicobacter pylori in esophagus and saliva in humans 81
THE INFLUENCE OF ACID REFLUX ON THE HEART RATE VARIABILITY (HRV) IN PATIENTS WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE (GERD) 81
COMBINED VIDEOCAPSULE ENDOSCOPY (VCE) AND LACTULOSE HYDROGEN BREATH TEST (LHBT): A COMPARATIVE STUDY TO ASSESS ORO-CECAL TRANSIT TIME (OCTT). 81
Alterazioni contrattili della muscolatura liscia nel corso di colite sperimentale sono ridotte da un antagonista specifico della sostanza P 81
Short- and long-term omeplazole for the tratment and prevention of duodenal ulcer, and effect on helicobacter pylori 80
Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. 80
Swallows, oesophageal and gastric motility in normal subjects and in patients with gastro-oesophageal reflux disease: a 24-h-pH-manometric study 79
Effect of glyceryl trinitrate ointment (GTO) 0.2% and 2% on anal canal pressure during acute and chronic application in patients with anal fissure 79
EFFICACY AND SAFETY OF LONG-TERM INFLIXIMAB USE FOR CROHN’S DISEASE IN SOUTHERN ITALY 79
THERAPY- RELATED ADVERS EVENTS IN CROHN’S DISEASE (CD) – A COMPARISON BETWEEN THIOPURINES, INFLIXIMAB AND COMBINED THERAPY 79
EVALUATION OF INTRAPARENCHYMAL AND PORTAL BLOOD FLOW BY CONTRAST ENHANCED ULTRASOUND (CEUS) AND LIVER STIFFNESS BY FIBROSCAN IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CHRONIC HEPATITIS C (CHC) 79
Effects of cimetropium bromide on gallbladder contraction in response to oral and intraduodenal olive oil. 79
Esophageal and gastric motility in patients with gastroesophageal reflux disease 78
GRAVIDANZA IN UNA PAZIENTE AFFETTA DA RETTOCOLITE ULCEROSA IN TERAPIA CON INFLIXIMAB: CASO CLINICO 78
H2-RECEPTOR ANTAGONISTS ARE SCAVENGERS OF OXYGEN RADICALS 78
SHORT AND LONG TERM EFFICACY OF GLYCERYL TRINITRATE (GTN) OINTMENT 0.2% AND 2% ON ANAL CANAL PRESSURE IN PATIENTS WITH CHRONIC ANAL FISSURES. 78
A “REAL LIVE” EXPERIENCE OF INFLIXIMAB USE FOR CROHN’S DISEASE IN SOUTHERN ITALY 78
EFFECT OF CLEBOPRIDE ON ESOPHAGEAL MOTOR FUNCTION IN GERD PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY: EVALUATION USING HIGH RESOLUTION MANOMETRY 78
PRUCALOPRIDE ACCELERATES GASTRIC AND SMALL BOWEL TRANSIT TIMES OF VIDEOCAPSULES ENDOSCOPY 78
RISPOSTA CLINICA E GUARIGIONE DELLA MUCOSA DOPO 4 ANNI DI TERAPIA CON INFLIXIMAB IN UN PAZIENTE CON MALATTIA DI CROHN ILEALE STEROIDO-RESISTENTE 77
TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS AND GASTRO-ESOPHAGEAL REFLUX EPISODES IN HEALTHY SUBJECTS AND GERD PATIENTS DURING 24 HOURS 77
EVALUATION OF INTRAPARENCHYMAL AND PORTAL BLOOD FLOW BY CONTRAST ENHANCED ULTRASOUND (CEUS) AND LIVER STIFFNESS BY FIBROSCAN IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CHRONIC HEPATITIS C (CHC). 77
EFFECT OF THE 5-HT3 RECEPTOR ANTAGONIST, ONDANSETRON, ON GASTRIC SIZE IN DYSPEPTIC PATIENTS WITH IMPAIRED GASTRIC ACCOMODATION 76
Increase of swallows before the onset of phase III of migrating motor complex in normal human subjects 76
TYPICAL AND ATYPICAL SYMPTOMS OF GASTRO ESOPHAGEAL REFLUX DISEASE: DOES Helicobacter pylori MATTER? 76
null 76
Gastric antral and fundus receptive relaxation in dyspeptic patients and normal subjects 75
Evidence for an oro-fecal transmission inan experimental murine model of helicobacter pylori infection. 75
LA MALDIGESTIONE 75
Peppermint oil (Mintoil®) in the treatment or irritable bowel syndrome: a prospective double blind placebo controlled randomized trial. 74
5-HT1-RECEPTOR AGONIST SUMATRIPTAN MODIFIES GASTRIC SIZE AFTER 500 ML OF WATER IN DYSPEPTIC PATIENTS AND NORMAL SUBJECTS 74
EFFICACY AND SAFETY OF INFLIXIMAB IN THE LONG-TERM IN CROHN’S DISEASE 74
Effect of omeprazole, clarithromicin and amoxicillin for a short time on helicobacter pylori eradication 73
ESOPHAGEAL MOTILITY ASSESSMENT AFTER PRUCALOPRIDE ADMINISTRATION IN PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY (IEM) AND SYSTEMIC SCLEROSIS. 73
Pharyngeal, Esophageal and Gastric Motility in Normal Subjects and in patients with gastroesophageal Reflux Disease 72
Erythromycin accellerates gastric and gallbladder emptying through a cholinergic mediated mechanism in humans 72
Proximal and Distal Gastric Distension in Normal Subjects and H.pylori-Positive and -Negative Dyspeptic Patients and Correlation with Symptoms 71
EFFECT OF HYOSCINE N-BUTYLBROMIDE ON GASTROESOPHAGEAL REFLUX IN NORMAL SUBJECTS AND PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE. 71
Oesophageal and gastric motility in patients with gastro-oesophageal reflux disease 70
Distensione gastrica nei soggetti normali e nei pazienti dispeptici helicobacter pylori positivi e negativi e correlazione con i sintomi 70
Role of transient lower esophageal sphincter relaxations in the genesis of priximal gastro-esophageal reflux 70
EFFICACIA E SICUREZZA DEL RITRATTAMENTO CON INFLIXIMAB IN UN PAZIENTE AFFETTO DA MORBO DI CROHN 70
EFFECT OF AN ACUTE INTRALUMINAL ADMINISTRATION OF CAPSAICIN ON OESOPHAGEAL MOTOR PATTERN IN GORD PATIENTS WITH INEFFECTIVE OESOPHAGAL MOTILITY 70
SPONTANEOUS OPENING OF LES IN ACHALASIA: AN UNCOMMON ON-LINE DOCUMENTATION BY HIGH-RESOLUTION MANOMETRY 70
I RILASCIAMENTI TRANSITORI DELLO SFINTERE ESOFAGEO INFERIORE NELLA GENESI DEI REFLUSSI GASTRO-ESOFAGEI: PROSPETTIVE TERAPEUTICHE 69
DISORDINI MOTORI ASPECIFICI DELL’ESOFAGO 69
CLINICAL AND ECONOMIC IMPACT OF INFLIXIMAB ONE-HOUR INFUSION PROTOCOL IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTER STUDY 69
Gastric antral and fundic distention evaluated by ultrasonography (US) in normal subjects and patients with idiopathic dyspepsia 68
EFFECT OF CIMETROPIUM BROMIDE ON GALLBLADDER CONTRACTION IN RESPONSE TO ORAL AND INTRADUODENAL OLIVE OIL 68
EFFECT OF THE 5-HT1 AGONIST SUMATRIPTAN ON ESOPHAGEAL MOTOR PATTERN IN PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY 68
CAN HELICOBACTER PYLORI INFECTION HAVE A ROLE ON CLINICAL APPEARANCE OF GERD? 68
EVALUATION OF LIVER BLOOD FLOW AND FIBROSIS IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CIRRHOSIS IN COMPARISON WITH NORMAL CONTROLS THROUGH CONTRAST ENHANCED ULTRASOUND(CEUS) AND FIBROSCAN 68
Mouth to caecum transit time (MCTT) is accellerated after oral food antigen in patients with irritable bowel syndrome 68
GASTRIC AND GALLBLADDER EMPTYING AFTER STANDARD SOLID MEAL IN NORMAL CONTROLS, PATIENTS WITH “MOTILITY-LIKE” DYSPEPSIA AND EFFECT OF DOMPERIDONE. 67
EVALUATION OF FIBROSIS AND INTRAPARENCHIMAL BLOOD FLOW INCHIRROTIC PATIENTS, CHRONIC ACTIVE HEPATITIS AND NORMAL CONTROLS THROUGH FIBROSCAN AND ULTRASOUND ENHANCED CONTRAST MEDIA. 67
THE VALUE OF CONTRAST ENHANCED ENDOSCOPIC ULTRASOUND IN THE FINE NEEDLE ASPIRATION 67
FPSE-HPLC-PDA METHOD FOR THE DETERMINATION OF INFLAMMATORY BOWEL DISEASE TREATMENT DRUGS IN WHOLE BLOOD, PLASMA AND URINE 67
Prolonged anal sphincter manometry in normal human subjects 66
ROLE OF PRUCALOPRIDE (RESOLOR) IN THE SETTING-UP OF PILLCAM COLON-CAPSULE ENDOSCOPY (CCE). EXPERIENCEFROM A SINGLE CENTRE 66
EVALUATION OF INTRA PARENCHYMAL AND PORTAL BLOOD FLOW BY CONTRAST ENHANCED ULTRASOUND (CEUS) AND FIBROSIS BY FIBROSCAN IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON ALCOHOLIC STEATOHEPATITIS (NASH) AND COMPARISON WITH NORMAL CONTROLS 66
LA MALATTIA DA REFLUSSO GASTROESOFAGEO 66
Registrazione delle 24 ore della motilità del piloro in soggetti normali 65
ON THE SPECIFICITY OF ALTERED MUSCLE FUNCTION IN EXPERIMENTAL COLITIS IN RATS 65
Effect of nitric oxide on propagated clusters of spontaneous motor waves in an ex vivo rabbit intestinal preparation 65
ULTRASOUND(US) GRADED HEPATOSTEATOSIS ASSESSMENT THROUGH CONTRAST ENHANCED ULTRASOUND (CEUS) AND FIBROSCAN IN NON ALCOHOLIC FATTY LIVER DISEASE 65
EFFICACY AND SAFETY OF GOLIMUMAB IN ULCERATIVE COLITIS. PRELIMINARY DATA FROM A MULTICENTER ITALIAN STUDY 65
Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis 65
Totale 8.321
Categoria #
all - tutte 40.282
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.282


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.535 0 0 0 0 208 329 351 270 43 124 203 7
2020/2021983 163 3 182 17 82 227 18 23 30 135 21 82
2021/2022789 35 15 4 200 46 16 24 66 54 9 88 232
2022/20232.154 188 207 108 264 194 488 145 158 253 41 59 49
2023/20241.002 79 51 62 36 34 292 236 37 14 44 19 98
2024/2025985 182 423 292 47 41 0 0 0 0 0 0 0
Totale 11.978